A GMP Protocol for the Manufacture of Tregs for Clinical Application

Alice O'Neil; Matthew Brook; Seetha Abdul-Wahab; Joanna Hester; Giovanna Lombardi; Fadi Issa

doi:10.1007/978-1-0716-2647-4_14

A GMP Protocol for the Manufacture of Tregs for Clinical Application

Methods Mol Biol. 2023:2559:205-227. doi: 10.1007/978-1-0716-2647-4_14.

Authors

Alice O'Neil¹, Matthew Brook¹, Seetha Abdul-Wahab¹, Joanna Hester¹, Giovanna Lombardi², Fadi Issa³

Affiliations

¹ Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
² MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, UK.
³ Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK. fadi.issa@nds.ox.ac.uk.

PMID: 36180635
DOI: 10.1007/978-1-0716-2647-4_14

Abstract

Infusion of regulatory T cells is a promising therapeutic strategy in organ transplantation to modulate the immune system, prevent rejection, minimize the need for pharmaceutical immunosuppression, and improve long-term transplant outcomes. Here we describe a GMP-compliant method we have used for the manufacture of ex vivo expanded autologous regulatory T cells for use in clinical trials.

Keywords: Immunosuppression minimization; Regulatory T cells; Tolerance; Transplantation; Treg.

MeSH terms

Graft Rejection / prevention & control
Immune Tolerance
Immunosuppression Therapy
Organ Transplantation*
Pharmaceutical Preparations
T-Lymphocytes, Regulatory*

Substances

Pharmaceutical Preparations

Abstract

MeSH terms

Substances

Grants and funding